Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's true that is the wrong chart, but did you like the news for RXi? that is awesome they can start distributing RXI-109 in Europe. That's awesome!
That's true that is the wrong chart, but did you like the news for RXi? that is awesome they can start distributing RXI-109 in Europe. That's awesome!
Nice article about Rxi's recent news for distribution of RXI-109 in Europe before regulatory approval. http://seekingalpha.com/instablog/17016892-biotech-pick-list/2424251-rxi-pharmaceuticals-receives-speical-provision-for-rxi-109
Rxi Pharmaceuticals signs agreement with Ethicor Pharmaceuticals to sell RXI-109 prior to regulatory approval under the "specials" EMA law. Under the law healthcare professionals can get access to a drug that treats patients with no other treatment options. http://finance.yahoo.com/news/rxi-pharmaceuticals-corporation-ethicor-ltd-120200896.html
Rxi Pharmaceuticals begins phase 2 study in patients with hypertrophic scars, will start with lower abdomen scars. Use effective control group by using one big scar. left side treated with drug RXI-109, middle nothing, right side placebo. http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-start-first-120200767.html
Just know that Arena will be a good long term stock to own. Today's move up of 10% shows the surge that could happen instantly. Stay long my friends. Check this article about Arena http://www.biotechpicklist.com/arena-pharmaceuticals-sky-rockets-back-into-orbit/
OTC market down the majority of the day so that is weird. But guys I want to let you know what I think. The CEO hasn't bought a share since october 30th, 2013. I think that we will have news possibly next week or the week after. I say this because insiders can't buy 2 weeks before a major catalyst.
Very good article talking about Arrowheads RNAi research for Hepatitis B virus. Good potential for this drug! http://seekingalpha.com/article/1808312-3-potential-game-changers-in-the-biotech-industry?source=yahoo
Very good article about RNAi therapeutics changing the future in medicine, was a good read. http://seekingalpha.com/article/1808312-3-potential-game-changers-in-the-biotech-industry?source=yahoo
New article out about RXII , it is a very good read for the future of RNAi stocks. http://seekingalpha.com/article/1808312-3-potential-game-changers-in-the-biotech-industry?source=yahoo
yes news will come out In november on the 2 additional cohorts added for multi dose results. I think with the low float and positive results we should see huge upside in RXII
Arena pharmaceuticals will take time but eventually I think it will come out strong. Eisai increasing marketing Belviq sales should help as well. http://seekingalpha.com/instablog/17016892-biotech-pick-list/2318222-arena-pharmaceuticals-is-poised-for-success
I couldn't get this published on Seeking Alpha but I have it posted on my seeking alpha instablog. Please let me know how it is! http://seekingalpha.com/author/biotech-pick-list/instablog
Very nice article out from seeking alpha today on RXII. Shows how low the value is, when it should be higher. http://seekingalpha.com/article/1743622-rxi-pharmaceuticals-is-undervalued-in-the-rnai-sector?source=yahoo
Yes dilution sucks, but think of it this way. We escaped this dilution, because yes it adds more shares to the float. But big money manager investors gobbled all $5.4 million of the shares. So as long as they hold them it's as if nothing happened really!
Good news for Rexahn pharmaceuticals. New CEO knows what he is doing to create shareholder value. All is good with my three trifecta biotechs Rxi Pharmaceuticals, Inovio, and Rexahn!
For BMSN investors you do realize what being listed on the pink sheets mean right? It means less disclosure! Meaning they don't have to list everything they do. The stock trades on the pinks sheets for good reason. I'm not trying to deter anyone from their goal of making money just be cautious. These stocks trade on the pink sheets because they don't have to disclose any part of their business they don't want to. They decide what gets shown to public.
Buyer Beware!
Investors should be aware of four cautions. First, most OTC stocks do not meet the minimum requirements for most exchanges and do not file with the SEC. Therefore, credible and reliable fundamental data are not available for analysis. Second, historically Pink Sheets stocks are penny stocks and are often near-insolvent companies. Third, some stocks are illegitimate shell companies set up to scam investors by issuing press releases, and having “analysts” promote the stock and issue more worthless shares. Fourth, Pink Sheets only has one requirement for a company to list - a company needs to have one market maker quoting its stock. The listing companies do not have to provide any financial information at all.
I told people time and time again he has run many companies in the past that he was a part of that either went bankrupt or disappeared off the map. He just starts companies on the pink sheets to keep his paycheck going! For instance now they have to run more animal tests before they can move on to the next step (so they claim).
Look at all past companies koos has been in. Either non existent or disappeared. That is how this guy keeps his paycheck going from investors. I'm glad that I didn't invest into this stock!
Isis advances Phase 2 Study For Infants With Spinal Muscular Atrophy http://www.biotechpicklist.com/isis-advances-phase-2-study-for-infants-with-spinal-muscular-atrophy/
What else is new? He has been doing it for years. Creating shell corporations to keep a paycheck!
Look at David Koos profile with all the companies he has been a part of, using them as shell companies for his profit. Check out one "Freezer Inc." under his profile on Forbes Look who runs it now one person, annual revenue of $94,000 dollars.
http://www.manta.com/c/mmg2wxd/freezer-inc
Smart move man, a lot of people haven't even done their research. Look how many shell companies David Koos has been a part of over the years. Some of them if you look them up on investorhub have gone to $0 share price, and some are non existent. He has been changing the names continuously throughout the years.
It's all in the news. If shorts were surprised today with positive news of FDA approval they would have covered and been forced to go long. The reason for the shorting is because they realize how bad the situation is. Do you honestly believe people short stocks for no reason? They see that now the trial will take another 6 month to 1 year with more dilution needed to run the trials.
Real investors are bailing out they know what's going on here. More dragged out trial in animal models for another year, more dilution etc. Glad to see that not all investors are fools!
So in essence you are telling me they won't have to run more animal tests?, and they won't have to dilute anymore to run the trials? You are also telling me they won't have to submit the animal tests back to FDA for approval? They are all facts, I know the truth hurts, but the truth is the truth!
It is fact, because that's the bottom line. The FDA wants more animal testing. That means they are not satisfied with the safety tests already done, they want to see more proof. That means 6 months to 1 year of more preclinical work, dilution to run the trial, and then they have to submit this info back to the FDA. Those are facts, not opinions.
Don't kid yourselves, Dilution is coming next on the table. Now that they have to run more animal tests it will take money to run the trial. Of which the trial will take 6 months to one year to complete at the pace this company moves. Don't let this company lead you on!
This drop was expected, they now have to run pre clinical tests against which can take another 6 months to 1 year, then they have to apply again for IND. Koos will dilute more to pay for his salary!
If you look at other biotech companies that trade on the NASDAQ they perform pre clinical tests and apply for IND's and boom they get approval even with new treatment methods like RNA helicase, ATK1 etc. No excuses if they had submitted enough tests from animal models the FDA would not have requested for more. Now it is going to be dragged out for another year!
That's what BMSN didn't tell you, they needed to run animal tests. Why didn't they do this before applying IND to the FDA. You always have to do animal tests before submitting an IND. You are correct bytor, now it will be another 6 months to a 1 year before the FDA even looks at the results from the animal models.
Wrong. NASDAQ capital market insists that applications take 6 to 8 weeks to process. The application was put in July 22nd so this week we are in week 8 since the application was put in. Next week we should hear something about the application.
I posted this on another board but I thought people should know why I think RXII will be going up over the next few months!
RXII is primed for lift off reason why!
1. Insider buying everyday as you mentioned
2. Uplist to NASDAQ this week or next
3. Phase 1 multidose extended for RXI-109 anti scarring by 2 more cohorts. Results prob by Nov/Dec
4. 2 phase 2 trials starting in 4th quarter 2013 - one for lower abdomen scars and the other for keloid scars
5. 3rd phase 2 trial starting 1st quarter 2014 for breast revision scar surgery
6. All 3 phase 2 trials will be updated by the first 3 months, 6 months and 9 months respectively. so results of phase 2 trials by Jan/ feb 2014.
Stay long and don't worry about these short term price decreases!
Anyways this coming week on Tuesday is the 7th week since NASDAQ application. So either this week or next week and we uplist to the NASDAQ Capital Market. I think it will turn things around for the better. I did not expect much trading on the OTCQX really!
RNN will bounce back over the next 2 days, it is not heading lower. Remember we have 2 phase 2a trials starting this quarter for Archexin. One is Archexin for blood cancer (Lymphoma) and the other is for a solid tumor. Good things are coming just load up shares and hang on!
if they get the Teva milestone payments for RX-3117 IND and phase 1 start they will have more than enough money!
One day it was 600 the other day it was 300 etc. Total he started with a position of 10,000 shares now it's up to 13,000 and still continues to buy! So 3,000 shares not the highest amount but still not the smallest. I'm sure he will continue to buy in increments to support the stock price!
We should be approaching NASDAQ listing anyways in the next 2 weeks so that will be a huge boost for the stock when we get more institutional investors in here!
Anyone else notice that the CEO is continuously buying shares 2 to 3 times a week for the last few weeks? He continues to add to his position! http://rxii.ir.edgar-online.com/fetchFilingFrameset.aspx?FilingID=9470935&Type=HTML
Something must be really good! Bullish to me when CEO buys every week like that!
Milestone payment from TEVA for RX-3117 you mean? or Archexin? Cause Archexin is not partnered but they are starting 2 trails in 2nd half 2013!
Anyone watching this closely? I see that Archexin is going to start 2 trials in 2nd half of 2013. One the CEO says will be in a blood cancer lymphoma, and the other will be a solid tumor cancer. I think that each trial announcement of phase 2 should boost the stock a little!